Research & Development (R&D) – Page 3

Tech transfer readiness gaps during transfer to manufacturing – data package improvements for filing

Effective communication among team members is essential for early detection of tech transfer readiness gaps. Symptoms can manifest in various forms, including:Click to read the full article.

Design space poorly justified during early development – how to ensure smooth tech transfer

Identifying anomalies early is critical in maintaining product integrity and compliance during the development phase. The symptoms associated with a poorly justified design space can manifest in various ways:Click to…

Process knowledge not captured during transfer to manufacturing – CAPA during development lifecycle

Identifying early signals of inadequate process knowledge transfer is essential for timely intervention. Common symptoms may include:Click to read the full article.

Method development instability during comparability assessment – downstream GMP risk and prevention

Recognition of instability in method development during a comparability assessment is critical in validating drug products. Symptoms can manifest in various ways, including:Click to read the full article.

Scale-up risk not identified during pilot scale – downstream GMP risk and prevention

Early recognition of symptoms or signals is essential in mitigating scale-up risks. Inadequate signaling can result in severe implications, including product quality issues or regulatory citations. The following symptoms typically…

Process knowledge not captured during comparability assessment – downstream GMP risk and prevention

Identifying the symptoms and signals of inadequate process knowledge is the first step in addressing the risks involved. Common signs include:Click to read the full article.

Excipient variability impact during scale-up – regulatory scrutiny implications

Identifying symptoms of excipient variability is crucial during scale-up. These symptoms can manifest in various ways, including:Click to read the full article.

Design space poorly justified during scale-up – how to ensure smooth tech transfer

When design space is inadequately justified during the scale-up phase, several signals may indicate underlying issues. It's essential to recognize these symptoms early to initiate timely interventions:Click to read the…

Process knowledge not captured during pilot scale – how to ensure smooth tech transfer

“`html Addressing Uncaptured Process Knowledge During Pilot Scale for Effective Tech Transfer In the pharmaceutical manufacturing environment, capturing comprehensive process knowledge during the pilot scale can often be overlooked, leading…

Excipient variability impact during comparability assessment – data package improvements for filing

Recognizing the signs of excipient variability is crucial for mitigating risks in drug development and manufacturing processes. Common indicators include:Click to read the full article.

Method development instability during comparability assessment – CAPA during development lifecycle

Identifying early signals of method development instability is crucial in mitigating potential impacts on the comparability assessment. Common symptoms to look out for include:Click to read the full article.

Design space poorly justified during transfer to manufacturing – downstream GMP risk and prevention

During manufacturing processes, various signals can indicate a poorly justified design space, which includes but is not limited to:Click to read the full article.